Biotech & Pharma

Beam Designs New Approach for Direct Correction of Mutations Causing PKU

26 sec read16 views0 listens

Beam Therapeutics launched BEAM-304, a new program using base editing technology to treat phenylketonuria (PKU), aiming to correct mutations in the PAH gene for patients with this rare metabolic disorder. This development is significant as it could reduce toxic phenylalanine levels and potentially eliminate lifelong dietary restrictions for PKU sufferers, highlighting the potential of genetic medicine to address unmet medical needs.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Ali NematiBlogUI.author_articles

BlogUI.view_profile

You Might Like

Cybersecurity8 hours ago29 sec read

Waiting for care: Why Canadians' healthcare expectations are colliding with reality

A new survey reveals that nearly half of Canadians waited longer than a week for their most recent routine medical appointment, despite expecting quicker access. This growing gap between expectations and reality highlights significant challenges in t...

Ali Nemati

Cybersecurity8 hours ago28 sec read

Q&A: The next threat to critical infrastructure is manipulation

Logan Spillner, Manager of Network Security at SHI, warns that attackers are increasingly targeting human decision-making in critical infrastructure rather than just technology systems. This cognitive warfare leverages AI to manipulate operators, pos...

Ali Nemati

Legal & Policy8 hours ago25 sec read

What A Torn Rotator Cuff Can Teach Us About Legal Business Development

A business development coach shares lessons from his recovery from a torn rotator cuff, drawing parallels between physical rehabilitation and building a successful law practice. He emphasizes that achieving goals requires sacrifice, following a struc...

Ali Nemati